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Epilepsy refers to chronic polyethyologic diseases of the brain characterized by recurrent seizures 
that occur as a result of excessive neuronal discharges and are accompanied by various clinical 
and paraclinical symptoms. Anticonvulsant therapy remains the basis for treating patients with 
epilepsy, which involves the inhibition or a significant reduction in the number of attacks. 
Currently, the term “antiepileptic” is synonymous with anticonvulsant agents, as they all selec-
tively suppress seizure, and their use is determined predominantly by the nature of paroxysmal 
manifestations or their equivalents. Depending on the clinical manifestations of epilepsy, diffe-
rent anticonvulsants can be prescribed. Often, for the treatment of epilepsy, the combined use of 
several medicines is rational (simultaneously or sequentially). Therefore, the success of a treat-
ment of epilepsy is on the way to finding new anticonvulsants, which would have had an effect on 
different pathogenetic links in the formation of all variabilities of seizure states [1].
Antiepileptic drugs act on different molecular targets, selectively changing the excitability 
of neurons in such a way that the neuronal activity, associated with attacks, is blocked without 
disturbing the normal activity required to transmit signals between neurons. Various mecha-
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nisms can lead to reducing the excitability of the neurons of the epileptogenic focus. Basically, 
they consist either in inhibiting activating neurons, or in activating inhibitory nerve cells, i. e, they 
are reduced to three major pharmaco-neurophysiological effects: relief of GABA or glycine-de-
pendent transmission, reduction of excitatory (glutamate or aspartate) transmission and non-
specific modification of ion currents (sodium, calcium, and potassium channels). At the same 
time, it is believed that the most effective control of seizure readiness is realized precisely because 
of GABA-ergic mechanisms [2, 3].
Despite the fact that these medicines take maximum account of the mechanisms of epilep-
togenesis, the issue of improving their effectiveness is still relevant.
A number of novel 3-substituted 1,4-benzodiazepines have been synthesized at the Phy sico-
Chemical Institute of the National Academy of Sciences of Ukraine, and their structure—acti-
vity relationships were studied [4]. Their pharmacological effect was unusual, as, unlike most 
drugs in this class, in the models of nociceptive and neuropathic pain, these substances showed 
a significant analgesic activity; one of them, propoxazepam, 7-bromo-5-(o-chlorophenyl)-3-
propoxy-1,2-dihydro-3H-1,4-benzodiazepin-2-one, is considered as a promising drug and is un-
dergoing preclinical trials.
Similar to gabapentin and pregabalin, which are well-known drugs used in general medical 
practice in the treatment of neuropathic pain [5], propoxazepam also has an anticonvulsant 
effect, which explains the analgesic component of the pharmacological spectrum [6—8].
The aim of this work is the propoxazepam pharmaological profile analysis on the models of 
different seizures (chemically and electrically induced) and the determination of the propoxa ze-
pam influence on manifestations and redistribution on different seizures for pharmacological indi-
ces (therapeutic index, therapeutic wideness, therapeutic interval and safety factor) calculation.
Materials and methods. Experiments were performed on outbred white mice of both sexes 
weighing 20-22 g. All experimental procedures were conducted in accordance with the rules of 
the “European Convention for the Protection of Vertebrate Animals, Used for Experimental and 
Other Scientific Purposes” in accordance with the Directive of the Council of the European Union 
86/609 of the EU of November 24 1986. During experiments the animals were kept under stan-
dard conditions (12-h light-shade mode and with access to water and food ad libitum).
The use of different seizures inducers (picrotoxin (PCT), penthylenetetrazole (PTZ), stry ch-
nine (STR), thiosemicarbazide (TSC), bemegride (BMG), 4-aminopyridine (4-AP), and ma-
ximal electroshock (MES) allowed us to model different paroxyzmal manifestations and to sug-
gest the propoxazepam mechanisms of antiseizure action.
The test compound was administered intraperitoneally (in a tween emulsion) at doses, 
whose choice of boundaries was based on previous pilot studies and the requirements of statistical 
and calculation methods. Solutions of chemoconvulsants (at doses causing the lethal effect in 
95 % of animals) were administered subcutaneously to animals (6—8 mice in each experimental 
group) 30 min after propoxazepam administration. The counting time of the experiment started 
from the mo ment of seizure agent administration. During the observation period, the number of 
myoclonic tremors and generalized attacks in the form of tonic extensia, as well as the time before 
the onset of the lethal effect, were recorded. To characterize the representativeness of each seizure 
types, the experimental data are presented in the relative form (M ± m) of the total number of 
recorded seizure episodes.
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Since the mechanism of convulsions development under the action of thiosemicarbazide 
involves a long exhaustion of endogenous GABA, the observation of animals was carried out 
within 3 h, indicating the number of individual components of convulsive attack (myoclonic 
tremor, generalized attacks in the form of tonic extension, the total number of cases of these 
types, and the time of their manifestation ) and total time to the lethal effect, marking the 
time periods since the chemoconvulsant administration. During the next 24 h, the end-lethal 
effect was recorded in each group of animals, which gave an opportunity to evaluate the possible 
time-dependent effects of propoxazepam and the general characteristic of its protective effect. 
The analysis of the lethal effect was carried out in an alternative form, by the number of animals 
that survived in experimental groups
Evaluation of the lethal effect was carried out in an alternative form (presence or absence 
of effect). The protective effect of the substance (the value of ED50) was estimated by the number 
of animals (frequency of effect) that survived in each individual group. The calculation of ED50 
values was carried out using the probability of developing the effect by the Kerber method 
(corrected by the Barren method) and probit analysis [9]. The reliability of the differences 
between the control and experimental groups for the individual parameters of convulsive acti-
vity (after the previous analysis for compliance with the normal distribution law), as well as the 
final experimental data, were assessed on the basis of the Student’s criteria or non-parametric 
statistics methods (Wilcoxon—Mann—Whitney Criteria) [10].
Results and their discussion. The results presented in table 1 indicate a high protective 
activity of propoxazepam based on the data of the dose-effect curves: PCT 1.67 ± 0.09, 
PTZ 0.9 ± 0.04, STR 14.24 ± 0.47, MES 0.57 ± 0.23, TSC 0.18 ± 0.09, 4-AP 37.3 ± 7.9 mg/kg. 
Changing the time of onset seizures and their redistribution in the course of an epileptic synd-
rome makes the compound promising in the epilepsy treating.
The specific feature of the used convulsive agents is the different structure of different seizu-
res representation. For nearly all the chemical convulsants used (except 4-AP), typically the ton-
ical component is represented as major (more than 70 %). It is possible that such ratio is de ter-
mined by the peculiarities in their action mechanisms and the rate of primary focal epilepsy center 
transformation to the dominant one with paroxysmal activity. For example, the most myoclonic 
component representation is noted for PCT, whose action mechanism is chloride ions current 
through the ionophore channel of GABAA-receptor with the simultaneous decrease of its average 
open-state time. PTZ is the most similar to PCT by its action mechanism, being the nondirect 
concurrent GABAA-receptor antagonist, having the binding sites in the cavity of the ionophore 
channel. Thus, for receptor channel blocking by PTZ, the primary activation of a re ceptor is neces-
sary, which explains the nearly absence of the clonic component in a PTZ-induced structure of 
seizures. For TSC, which blocks the GABA reserve restoring, the fast generalization of excitation, 
leading to the development of tonic seizures (mostly 100 % of seizures) is the main feature. Despite 
the BMG action also develops through the GABA-ergic system (barbitura te-binding site blo-
cker), there is also a little manifestation of the myoclonic component (2 %). The higher part of the 
myoclonic component (5.8 %) is in STR-induced seizures (concurrent antagonist of glycine re-
ceptors, mainly concentrated in the spinal cord and controlling peripheral signals transmission).
Convulsive action of MES develops through the total depolarization of brain neurons, 
caused by electric discharge, which generates the tonical component of seizures. Among the 
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described convulsants, the myoclonic component is mostly represented (67 %) in the 4-AP-in-
duced seizures, whose action mechanism is in the potassium channels blocking and repolariza-
tion inhibition.
The results obtained provide the possibility to determine the proxazepam antiseizure pro-
file in various models of epileptic seizure, taking into account that the development of tonic 
seizures is associated with more severe and generalized CNS excitations, which is more difficult 
to block as compared to the formation of primary epileptopoietic focci (which are accompanied 
by myoclonic types of convulsions). The effect of propoxacepam on the structure of the epilep-
tic attack was evaluated at the dose, which has the maximum protective effect, but does not block 
the development of separate types of seizures (see Table 1). Depending on the type of сhemo con-
vulsant, the protective dose of propoxazepam is significantly different (from 0.32 mg/kg for 
TSC up to 80 mg/kg for 4-AP), indicating a different degree of interaction with biotargets. 
Obviously, propoxazepam is more effective on the GABA-ergic dysfunction models, what is pro-
ved by a rise of the myoclonic component repre sentation in the seizures structrure with the si mul-
ta neous decrease of the tonic component. We have to mention that, on the BMG-induced seizures 
model, the relative quantity of the myoclonic component is only 32 %. This suggests the com-
paratively separate influence of benzdiazepine- and bar biturate-allosteric centers control.
MES-induced seizures blocking demands the strong and steady cells hyperpolarization. 
Thus, the propoxazepam efficiency in this model is not very high. Moreover, even the relatively 
high doses (20 mg/kg) don’t suppress the tonic component (68 %) possessing nevertheless, the 
protective action.
The attention is attracted by the fact that in the model of 4-AP-induced seizures, propox-
azepam not only shares the negligible effect (94 % of protective action is reached at a dose of 
Table 1. LD95 indices of different convulsion-inducing agents, propoxazepam ED50 
and the relative representation of the clonic and tonic components in mice, 
as well as their change with the propoxazepam administration
Seizures type
PCT PTZ STR TSC BMG 4-AP MES
LD95 (mg/kg)
6.5 120.0 2.0 20.0 56.0 10.3
Propoxazepam. ЕD50 (mg/kg)
1.67 ± 0.09 0.9 ± 0.1 14.2 ± 0.5 0.2 ± 0.09 0.39 ± 0.1 37.3 ± 8 0.57 ± 0.3
The relative quantity of different seizures in the control group
Myoclonic 25 0 6 0 2 67 0
Tonic 75 100 94 100 98 33 100
Seizures type
Propoxazepam dose (mg/kg) and maximal reached protective effect (%)
8
(100 %)
3
(100 %)
32
(80 %)
0.32
(100 %)
0.8
(100 %)
80
(94 %)
20
(100 %)
Myoclonic 93 65 26 75 32 13 32
Tonic 7 35 74 25 68 87 68
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80 mg/kg), but also unusually redistributes the myoclonic and tonic components (reducing 
the firs and increasing the second component).
Such peculiarities in the anticonvulsant action can be explained from the position of po-
tassium ion channels functioning, which are inhibited by 4-AP. It is known that their activation 
leads to the membrane repolarization after the action potential development (participation in 
the potential restoring). Thus, paying attention to such an “antiepileptic” effect, it is possible to 
suggest the division of propoxazepam and 4-AM actions — first one acts predominantly on post-
synaptic GABAA-receptors, causing the cell hyperpolarization, while the second interferes both 
pre- and postsynaptic potassium channels of the cell. Obviously, such an influence leads not only 
to the hyperpolarization efficiency reducing, but also increases the cell refractory period. Be cause 
of it, even the high doses of propoxazepam doesn′t share the 100-% efficiency in this model.
On the base of the obtained data, the main indices (therapeutic index, therapeutic wide ness, 
and safety factor), which characterize the propoxazepam safety use, were calculated. Therapeutic 
index (TI) determines the interval between the equipotential doses (causing the equivalent ef-
fect in %). Usually, it is determined as the ratio of mean effective doses of the lethal (LD50) 
and therapeutic (ED50) effects — the bigger this indicator, the more safe the medicine use.
Therapeutic wideness (or “therapeutic window”, TW) is the dose diapason between the 
minimal therapeutic and minimal toxic ones. As the accuracy of the compound minimal toxic 
dose value depends on the quantity of subjects, its empirical values are changed to calculate 
the threshold effect (1 %), TW = (TD1—ED1). This indicator characterizes the doses interval, 
which can be used without toxic effects appearing. It is a more reliable safety indicator, since it 
reflects the degree of side effects appearing on the dose-effect curve. As its dimension is dose-de-
pendent, it is used together with the Therapeutic Interval (TInt) indicator, which represents the 
compound influence on organism (TInt = ED99—ED1). The higher this indicator, the higher the 
dose needed for the desired effect reaching. These intervals overlapping (TW  TInt) testifies to the 
toxic effects appearing at doses, which cause no therapeutic effect at most of treated subjects.
Safety factor (SF) is the ratio of minimal toxic dose to maximal effective one (SF = TD1/
ED99) and reflects the possibility of degree, in which the therapeutic dose can be increased 
without the risk of intoxication. As well as the therapeutic index, SF is a dimensionless para-
meter and can be used for the comparative estimation of different compounds. Because, during 
the LD50 determination, the lethal effect hadn’t been reached, the lower limit in the further cal-
culations was assumed to be a 5000 mg/kg as that tested in the experiment. This value became 
the basis for the comparative characterization of the 
compound safety under the conditions of different gen-
esis seizures. The given data (table 2, figure) prove that 
the highest propoxazepam safety is in the PTZ-induced 
epileptic syndrome (clonical, clonical-tonical and gen-
eralized seizures), because, for this model, the highest 
values of all the indicators are determined (see table 2) 
along with low TInt value, which suggests the quick ef-
fect increase with the raising dose. The high TI values 
for TSC and MES tests (see table 2) also de monstrate a 
high safety of the compound use at GABA-deficient 
Table 2. Propoxazepam safety indices
Seizure 
inducer 
in test
TI SF TW TInt
PTZ 5556 4379 5000 0.33
PCT 2994 2243 4999 0.75
TSC 27778 1908 5000 2.6
MES 10000 851.0 5000 5.7
STR 351 294.2 4988 3.8
4-AP 134 43.1 4988 93
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pathologies and primary-generalized seizures (status epilepticus), as well as partial paroxyzms 
in the MES model. But the TW factor is notably reduced (1908 and 851, respectively, see fig-
ure). Moreover, as compared to the PTZ-induced seizures test, this indicator shows no signi-
ficant effect increase with dose raise. Both effective dose and TInt increase for propoxazepam 
suggest its little possibility to block STR- and 4-AP-induced paro xyzmal manifestations. Thus, 
the SF values proved that the propoxazepam use is more safe and efficient for the treatment 
of pathologies, which correspond to its mechanism of action.
Comparison of the spectrum of anticonvulsant action of propoxazepam with the majority 
of medicines used to suppress specific epileptic syndrome (table 3) showed its preference. Only 
valproate, as in propoxazepam, is characterized by the inhibition of all variabilities of convulsive 
states. According to the main hypothesis, valproate stimulates GABA-ergic mechanisms, by in-
hibiting the GABA-transferase enzyme, which leads to an increase in the content of GABA in the 
Comparative propoxazepam characterization on the base of TI (therapeutic index) 
and SF (safety factor) values
Table 3. The effectiveness of antiepileptic medicines for different types of seizures
Medicines
Seizures type
Partial Tonic-clonic Absences Myoclonic Atonic-tonic
Phenobarbital + + + 0 ?
Phenytoin + + — — 0
Carbamazepine + + + + 0
Valproate + + + + +
Tomiramat + + ? + +
Gabapentin + + — — 0
Lamotrigine + + + + +
Ethosuxumide 0 0 + 0 0
Levetiracetam + + + + ?
Felbamate + + ? + +
Vigabatrin + + — — ?
Propoxazepam + + + + +
Note. “+” — effective; “? + “— maybe effective; “0” — ineffective; “—” — increased attacks; “?” — unknown
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central nervous system. Another mechanism for increasing the GABA-ergic activity is the di-
rect influence of valproate on postsynaptic receptors (especially, GABA-RK), which simulates 
or enhances the effect of GABA. In addition, the drug has a direct effect on the potential-de-
pendent sodium channels and can affect the activity of the membranes, changing the permeabi-
lity for potassium ions [11].
At the same time, when comparing experimental data on the “gold standard” of screening 
drugs on models of seizures caused by PTZ and MES [12], it is noticeable that, according to 
the values of ED50, propoxazepam predominates valproate [propoxazepam (0.92 ± 0.38/0.57 ±
± 0.23 mg/kg), valproate (271.7/148.6)].
Taking into account the fact that propoxazepam refers to derivatives of 1,4-benzodiazepine, it 
is necessary to compare the indicated parameters with the drugs of this group. So, diazepam has 
the following ratio of MES/PTZ tests in mice, mg/kg (3.5/0.52); clonazepam (7.5/0.06); ni-
trazepam (4.5/0.27); phenobarbital (21.8/13.2). Some anticonvulsants (phenytoin, carba ma-
zepine) do not affect seizures caused by penthylenetetrazole, but are active in relation to MES 
(9.5 and 8.8, respectively). With regard to the significant difference in the ratios of MES/PTZ 
ratios of related compounds (1,4-benzodiazepines) having similar mechanisms of action, their 
explanation may be data on the structure of GABA-RK for which the effect of PTZ is often cha-
racterized as “noncompetitive” in relation to anticonvulsants of 1,4-benzodiazepine [13]. Note 
that the part of GABA-RK is represented by a number of subtypes, among which a4b3d, a3bg2, 
a3bg2, a1bg2 are responsible for the seizure effect of chemoconvulsants. Moreover, each benzo-
diazepine prefers a specific receptor subtype [14]. So, diazepam, clonazepam, and nitrazepam 
are high-affinity compounds of a2 and a3 receptors.
The results of the study prove the high safety of propoxazepam use for the treatment of 
GABA-associated pathologies and primary-generalized seizures (status epilepticus) in the tests of 
TSC- and MES-induced seizures, as well as MES-induced partial paroxizmas.
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ФАРМАКОЛОГІЧНИЙ ПРОФІЛЬ ПРОПОКСАЗЕПАМУ —
 НОВОГО ПРОТИЕПІЛЕПТИЧНОГО ЗАСОБУ
Проведено аналіз залежності “доза—ефект” фармакологічної дії пропоксазепаму на моделях судом у ми-
шей, викликаних специфічними хімічними та електричними конвульсантами. Визначено особливості 
впливу сполуки на перебіг та перерозподіл судом різного ґенезу. Розраховано фармакологічні показники 
(терапевтичний індекс, широта, інтервал та фактор надійної безпеки), що характеризують ефективність 
та безпечність пропоксазепаму. Одержані дані свідчать про те, що застосування пропоксазепаму як про-
тие пілептичного засобу є більш безпечним у випадку тих патологій, що у більшому ступені відповідають 
його ГАМКА- та гліцин-ергічним механізмам дії.
Ключові слова: пропоксазепам, хімічні та електричні конвульсанти, терапевтичний індекс, широта, ін-
тервал, фактор надійної безпеки.
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ФАРМАКОЛОГИЧЕСКИЙ ПРОФИЛЬ ПРОПОКСАЗЕПАМА — 
НОВОГО ПРОТИВОЭПИЛЕПТИЧЕСКОГО СРЕДСТВА
Проведен анализ зависимости “доза—эффект” фармакологического действия пропоксазепама на моде лях 
судорог у мышей, вызванных специфическими химическими и электрическими конвульсантамы. Оп ре-
делены особенности влияния соединения на течение и перераспределение судорог различного генезиса. 
Рассчитаны фармакологические показатели (терапевтический индекс, широта, интервал и фактор на-
дежной безопасности), характеризующие эффективность и безопасность пропоксазепама. Полученные 
данные свидетельствуют о том, что применение пропоксазепама как противоэпилептического средства 
является более безопасным при тех патологиях, что в большей степени соответствуют его ГАМКА- и 
глицин-эргическим механизмам действия.
Ключевые слова: пропоксазепам, химические и электрические конвульсанты, терапевтический индекс, 
широта, интервал, фактор надежной безопасности.
